Table 1.
Clinical trials on the bi-inhibition of TIGIT and PD-1/PD-L1 registered on clinicaltrials.gov
| No | NCT number | Phase | Status | Cancer | Drug(s) of Intervention Arm(s) | Drug(s) of Control Arm(s) | Outcomes | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04948697 | 2 | Active, not recruiting | Advanced Liver Cancers | Ociperlimab plus Tislelizumab plus BAT1706 | Tislelizumab plus BAT1706 | - | |||||||
| 2 | NCT05724563 | 2 | Not yet recruiting | Advanced Liver Cancers | Zimberelimab plus Domvanalimab | - | - | |||||||
| 3 | NCT04524871 | 1/2 | Recruiting | Advanced Liver Cancers | Atezolizumab plus Bevacizumab plus Tiragolumab |
Atezolizumab plus Bevacizumab Atezolizumab plus Bevacizumab plus Tocilizumab Atezolizumab plus Bevacizumab plus TPST-1120 RO7247669 plus Bevacizumab Atezolizumab plus Bevacizumab plus ADG126 |
- | |||||||
| 4 | NCT04911894 | 1 | Completed | Advanced Solid Tumor | IBI321 | - | - | |||||||
| 5 | NCT04911881 | 1 | Completed | Advanced Solid Tumor | IBI321 | - | - | |||||||
| 6 | NCT02913313 | 1/2 | Active, not recruiting | Advanced Solid Tumor |
BMS-986,207 plus nivolumab BMS-986,207 plus nivolumab plus ipilimumab BMS-986,207 |
- | - | |||||||
| 7 | NCT02794571 | 2 | Active, not recruiting | Advanced Solid Tumor | Atezolizumab plus Tiragolumab | - |
ORRdual: 46% (6/13) DCRdual: 85% (11/13) |
|||||||
| 8 | NCT02964013 | 1 | Active, not recruiting | Advanced Solid Tumor |
Vibostolimab plus pembrolizumab Vibostolimab plus pembrolizumab plus chemotherapy MK-7684 A Vibostolimab plus chemotherapy Vibostolimab |
- |
ORRdual: 26% mPFSdual: 8.4 months |
|||||||
| 9 | NCT04570839 | 1/2 | Active, not recruiting | Advanced Solid Tumor | COM701 plus BMS-986,207 plus Nivolumab | - |
ORRdual: 20% (4/20) DCRdual: 45% (9/20) |
|||||||
| 10 | NCT03628677 | 1 | Active, not recruiting | Advanced Solid Tumor |
Domvanalimab plus Zimberelimab Domvanalimab |
- | - | |||||||
| 11 | NCT04457778 | 1 | Active, not recruiting | Advanced Solid Tumor |
M6223 plus Bintrafusp alfa M6223 |
- | - | |||||||
| 12 | NCT04632992 | 2 | Active, not recruiting | Advanced Solid Tumor | Atezolizumab plus Tiragolumab |
Entrectinib Inavolisib Alectinib Ipatasertib Atezolizumab plus Investigator’s Choice of Chemotherapy Trastuzumab Emtansine plus Atezolizumab Pertuzumab plus Trastuzumab plus Hyaluronidase-zzxf Pertuzumab plus Trastuzumab plus Hyaluronidase-zzxf plus Investigator’s Choice of Chemotherapy Trastuzumab Emtansine plus Tucatinib Trastuzumab Emtansine plus Atezolizumab Ipatasertib plus Atezolizumab Ipatasertib plus Paclitaxel Pralsetinib |
- | |||||||
| 13 | NCT03260322 | 1 | Completed | Advanced Solid Tumor |
ASP8374 plus Pembrolizumab ASP8374 |
- | - | |||||||
| 14 | NCT04353830 | 1 | Completed | Advanced Solid Tumor |
IBI939 plus Sintilimab IBI939 |
- | - | |||||||
| 15 | NCT04335253 | 1 | Completed | Advanced Solid Tumor | EOS-448 | - | - | |||||||
| 16 | NCT03945253 | 1 | Completed | Advanced Solid Tumor | ASP8374 | - | - | |||||||
| 17 | NCT05172856 | 1 | Not yet recruiting | Advanced Solid Tumor | IBI321 | - | - | |||||||
| 18 | NCT05483400 | 2 | Not yet recruiting | Advanced Solid Tumor | Tiragolumab plus Atezolizumab | - | - | |||||||
| 19 | NCT05259319 | 1 | Not yet recruiting | Advanced Solid Tumor | Atezolizumab plus Tiragolumab plus SBRT | - | - | |||||||
| 20 | NCT05537051 | 1 | Not yet recruiting | Advanced Solid Tumor |
PM1021 plus PM8001 PM1021 |
- | - | |||||||
| 21 | NCT05715281 | 2 | Not yet recruiting | Advanced Solid Tumor | Atezolizumab plus Tiragolumab | - | - | |||||||
| 22 | NCT05661578 | 2 | Recruiting | Advanced Solid Tumor | Tiragolumab plus Atezolizumab | - | - | |||||||
| 23 | NCT05286801 | 1/2 | Recruiting | Advanced Solid Tumor | Atezolizumab plus Tiragolumab | - | - | |||||||
| 24 | NCT03977467 | 2 | Recruiting | Advanced Solid Tumor | Atezolizumab plus Tiragolumab | Atezolizumab plus chemotherapy | - | |||||||
| 25 | NCT04047862 | 1 | Recruiting | Advanced Solid Tumor |
Ociperlimab plus Tislelizumab Ociperlimab plus Tislelizumab plus chemotherapy Ociperlimab |
- | ORRdual: 57.5% vs. ORRdual+C: 54.8% | |||||||
| 26 | NCT05417321 | 1/2 | Recruiting | Advanced Solid Tumor | HB0036 | - | - | |||||||
| 27 | NCT05026606 | 2 | Recruiting | Advanced Solid Tumor | Etigilimab plus Nivolumab | - | - | |||||||
| 28 | NCT04761198 | 1/2 | Recruiting | Advanced Solid Tumor | Etigilimab plus Nivolumab | - | - | |||||||
| 29 | NCT04354246 | 1 | Recruiting | Advanced Solid Tumor |
COM902 plus COM701 plus Pembrolizumab COM902 plus COM701 COM902 |
- | - | |||||||
| 30 | NCT05120375 | 1 | Recruiting | Advanced Solid Tumor | BAT6021 | - | - | |||||||
| 31 | NCT05073484 | 1 | Recruiting | Advanced Solid Tumor |
BAT6021 plus BAT1308 BAT6021 |
- | - | |||||||
| 32 | NCT05060432 | 1/2 | Recruiting | Advanced Solid Tumor |
EOS-448 plus Pembrolizumab EOS-448 plus Inupadenant EOS-448 plus Dostarlimab EOS-448 plus Dostarlimab plus Inupadenant EOS-448 plus Dostarlimab plus chemotherapy |
Inupadenant plus Dostarlimab | - | |||||||
| 33 | NCT05007106 | 2 | Recruiting | Advanced Solid Tumor |
MK-7684 A MK-7684 A plus Lenvatinib MK-7684 A plus 5-Fluorouracil plus Cisplatin MK-7684 A plus Paclitaxel MK-7684 A plus Gemcitabine/Cisplatin MK-7684 A plus Carboplatin/Paclitaxel/Bevacizumab MK-7684 A plus Capecitabine/Oxaliplatin |
Pembrolizumab | - | |||||||
| 34 | NCT04446351 | 1 | Recruiting | Advanced Solid Tumor |
EOS-448 plus Dostarlimab EOS-448 plus Dostarlimab plus GSK6097608 |
GSK6097608 GSK6097608 plus Dostarlimab Dostarlimab Dostarlimab plus Cobolimab |
- | |||||||
| 35 | NCT03869190 | 1/2 | Recruiting | Advanced Solid Tumor | Atezolizumab plus Tiragolumab |
Atezolizumab Atezolizumab plus Enfortumab Vedotin Atezolizumab plus Niraparib Atezolizumab plus Magrolimab Atezolizumab plus Sacituzumab Govitecan Atezolizumab plus RO7122290 Cisplatin |
- | |||||||
| 36 | NCT05757492 | 1/2 | Recruiting | Advanced Solid Tumor | JS006 plus Toripalimab | - | - | |||||||
| 37 | NCT05394337 | 1 | Not yet recruiting | Advanced Urothelial Carcinoma | Neoadjuvant atezolizumab plus Tiragolumab | - | - | |||||||
| 38 | NCT05845814 | 1/2 | Not yet recruiting | Advanced Urothelial Carcinoma | MK-7684 A plus EV |
Coformulated Favezelimab/Pembrolizumab plus EV Pembrolizumab plus EV |
- | |||||||
| 39 | NCT05327530 | 2 | Recruiting | Advanced Urothelial Carcinoma | Avelumab plus M6223 |
Avelumab Avelumab plus Sacituzumab Govitecan Avelumab plus NKTR-255 |
- | |||||||
| 40 | NCT03547973 | 2 | Recruiting | Advanced Urothelial Carcinoma | Sacituzumab Govitecan-hziy plus Zimberelimab plus Domvanalimab |
Sacituzumab Govitecan-hziy Sacituzumab Govitecan-hziy plus Pembrolizumab Sacituzumab Govitecan-hziy plus Cisplatin plus Avelumab Sacituzumab Govitecan-hziy plus Cisplatin plus Zimberelimab Sacituzumab Govitecan-hziy plus Zimberelimab Avelumab Zimberelimab Carboplatin plus Gemcitabine |
- | |||||||
| 41 | NCT05645692 | 2 | Recruiting | Advanced Urothelial Carcinoma | Tiragolumab plus R07247669 |
RO7247669 Atezolizumab |
- | |||||||
| 42 | NCT05023109 | 2 | Recruiting | Biliary Tract Carcinoma | Tislelizumab plus Ociperlimab plus chemotherapy | - | - | |||||||
| 43 | NCT02625961 | 2 | Recruiting | Bladder Cancer | MK-7684 A | Pembrolizumab | - | |||||||
| 44 | NCT04693234 | 2 | Active, not recruiting | Cervical Cancer | Tislelizumab plus Ociperlimab | Tislelizumab | - | |||||||
| 45 | NCT04300647 | 2 | Active, not recruiting | Cervical Cancer | Tiragolumab plus Atezolizumab | Atezolizumab | - | |||||||
| 46 | NCT04895722 | 2 | Recruiting | Colorectal Cancer | MK-7684 A |
Pembrolizumab Co-formulated Pembrolizumab/Quavonlimab Co-formulated Pembrolizumab/Favezelimab Pembrolizumab Plus MK-4830 |
- | |||||||
| 47 | NCT04929223 | 1 | Recruiting | Colorectal Cancer |
Atezolizumab plus Tiragolumab plus Bevacizumab Atezolizumab plus Tiragolumab |
Inavolisib plus Cetuximab Inavolisib plus Bevacizumab Atezolizumab plus SY-5609 GDC-6036 plus Cetuximab plus FOLFOX GDC-6036 plus Cetuximab |
- | |||||||
| 48 | NCT04486352 | 1/2 | Recruiting | Endometrial Cancer | Atezolizumab plus Tiragolumab |
Atezolizumab plus Bevacizumab Atezolizumab plus Ipatasertib Atezolizumab plus Talazoparib Atezolizumab plus Trastuzumab emtansine (TDM-1) Inavolisib plus Letrozole |
- | |||||||
| 49 | NCT04540211 | 3 | Active, not recruiting | ESCC | Tiragolumab plus Atezolizumab plus chemotherapy | Placebo plus chemotherapy | - | |||||||
| 50 | NCT05743504 | 1/2 | Not yet recruiting | ESCC | Tiragolumab plus Atezolizumab with CCRT before surgery | - | - | |||||||
| 51 | NCT04732494 | 2 | Recruiting | ESCC | Tislelizumab plus Ociperlimab | Tislelizumab plus Placebo | - | |||||||
| 52 | NCT04543617 | 3 | Recruiting | ESCC |
Tiragolumab plus Atezolizumab Tiragolumab |
Atezolizumab plus Placebo | - | |||||||
| 53 | NCT03281369 | 1/2 | Recruiting | ESCC |
Atezolizumab plus Tiragolumab plus chemotherapy Atezolizumab plus Tiragolumab |
Atezolizumab | - | |||||||
| 54 | NCT04933227 | 2 | Active, not recruiting | Gastric Cancer | Tiragolumab plus Atezolizumab plus chemotherapy | - | - | |||||||
| 55 | NCT05251948 | 1/2 | Active, not recruiting | Gastric Cancer | Tiragolumab plus Atezolizumab plus chemotherapy | Atezolizumab plus chemotherapy | - | |||||||
| 56 | NCT05568095 | 3 | Recruiting | Gastric Cancer | Zimberelimab plus Domvanalimab plus chemotherapy | Nivolumab plus chemotherapy | - | |||||||
| 57 | NCT05329766 | 2 | Recruiting | Gastric Cancer |
Domvanalimab plus Zimberelimab plus chemotherapy Domvanalimab plus Zimberelimab |
Zimberelimab plus chemotherapy Zimberelimab plus Quemliclustat |
- | |||||||
| 58 | NCT05702229 | 2 | Recruiting | Gastric Cancer | AZD2936 Plus XELOX/FOLFOX | MEDI5752 plus XELOX/FOLFOX | - | |||||||
| 59 | NCT04826393 | 1 | Active, not recruiting | Glioblastoma | ASP8374 plus Cemiplimab | - | - | |||||||
| 60 | NCT04656535 | 1 | Recruiting | Glioblastoma |
AB122 plus Domvanalimab plus surgery AB122 plus Domvanalimab Domvanalimab plus surgery |
AB122 plus surgery surgery |
- | |||||||
| 61 | NCT05130177 | 2 | Recruiting | Melanoma | Zimberelimab plus Domvanalimab | - | - | |||||||
| 62 | NCT05665595 | 3 | Recruiting | Melanoma | Pembrolizumab plus Vibostolimab | Pembrolizumab | - | |||||||
| 63 | NCT05060003 | 2 | Recruiting | Melanoma | Atezolizumab plus Tiragolumab | Atezolizumab | - | |||||||
| 64 | NCT04305041 | 1/2 | Recruiting | Melanoma | Pembrolizumab plus Quavonlimab plus Vibostolimab |
Pembrolizumab plus Quavonlimab plus Lenvatinib Pembrolizumab plus all-trans retinoic acid (ATRA) |
- | |||||||
| 65 | NCT04305054 | 1/2 | Recruiting | Melanoma |
Pembrolizumab plus Vibostolimab Coformulation Favezelimab/Pembrolizumab plus Vibostolimab |
Pembrolizumab Coformulation Pembrolizumab/Quavonlimab Coformulation Pembrolizumab/Quavonlimab plus Lenvatinib Coformulation Favezelimab/Pembrolizumab Coformulation Favezelimab/Pembrolizumab plus All-trans Retinoic Acid (ATRA) |
- | |||||||
| 66 | NCT04303169 | 1/2 | Recruiting | Melanoma | Pembrolizumab plus Vibostolimab |
Pembrolizumab plus Gebasaxturev Pembrolizumab Pembrolizumab plus MK-4830 Favezelimab plus Pembrolizumab Pembrolizumab plus all-trans retinoic acid (ATRA) |
pCRdual: 38% vs. pCRP: 40% pPRdual: 31% vs. pPRP: 27% RFSdual (18 m): 95% vs. RFSP (18 m): 73% ORRdual: 50% vs. ORRP: 27% EFSdual (18 m): 81% vs. EFSP (18 m): 79% |
|||||||
| 67 | NCT03554083 | 2 | Recruiting | Melanoma | Atezolizumab plus Tiragolumab |
Vemurafenib plus Cobimetinib plus Atezolizumab Cobimetinib plus Atezolizumab |
- | |||||||
| 68 | NCT05116202 | 1/2 | Recruiting | Melanoma |
Atezolizumab plus Tiragolumab RO7247669 plus Tiragolumab |
Nivolumab plus Ipilimumab RO7247669 |
- | |||||||
| 69 | NCT02861573 | 1/2 | Recruiting | Metastatic Castration-Resistant Prostate Cancer | MK-7684 A |
Pembrolizumab plus Olaparib Pembrolizumab plus Docetaxel plus Prednisone Pembrolizumab plus Enzalutamide Pembrolizumab plus Abiraterone plus Prednisone Pembrolizumab plus Lenvatinib Pembrolizumab plus Carboplatin plus Etoposide Carboplatin plus Etoposide Belzutifan Pembrolizumab plus Belzutifan |
- | |||||||
| 70 | NCT04672356 | 1 | Active, not recruiting | NSCLC | IBI939 plus Sintilimab | - | - | |||||||
| 71 | NCT04672369 | 1 | Active, not recruiting | NSCLC | IBI939 plus Sintilimab | Sintilimab |
ORRdual: 66.7% (18/27) vs. ORRP: 61.5% (8/13) mPFSdual: NR vs. mPFSP: 6.0 m (HR = 0.43) |
|||||||
| 72 | NCT03563716 | 2 | Active, not recruiting | NSCLC | Atezolizumab plus Tiragolumab | Atezolizumab plus Placebo |
ORRdual: 31.3% vs. ORRP: 16.2% mPFSdual: 5.4 m vs. mPFSP: 3.6 m (HR = 0.57) |
|||||||
| 73 | NCT04725188 | 2 | Active, not recruiting | NSCLC |
MK-7684 A plus chemotherapy MK-7684 A |
chemotherapy | Did not reach statistical significance for PFS and was numerically less effective than Docetaxel | |||||||
| 74 | NCT04262856 | 2 | Active, not recruiting | NSCLC |
Zimberelimab plus Domvanalimab plus Etrumadenant Zimberelimab plus Domvanalimab |
Zimberelimab |
ORRdual+O: 40% vs. ORRdual: 41% vs. ORRP: 27% mPFSdual+O: 10.9 m vs. mPFSP: 5.4 m (HR = 0.65) mPFSdual: 12.0 m vs. mPFSP: 5.4 m (HR = 0.55) |
|||||||
| 75 | NCT03819465 | 1 | Active, not recruiting | NSCLC |
AZD2936 AZD2936 plus chemotherapy |
Durvalumab Durvalumab plus danvatirsen Durvalumab plus oleclumab MEDI5752 Durvalumab plus Investigator’s choice of chemotherapy Durvalumab plus Investigator’s choice of chemotherapy plus danvatirsen Durvalumab plus investigator’s choice of chemotherapy plus oleclumab |
- | |||||||
| 76 | NCT04585815 | 2 | Active, not recruiting | NSCLC | SEA-TGT plus sasanlimab plus Axitinib | Sasanlimab plus Encorafenib plus inimetinib | - | |||||||
| 77 | NCT05034055 | 2 | Not yet recruiting | NSCLC | Atezolizumab plus Tiragolumab plus SBRT | - | - | |||||||
| 78 | NCT05798663 | 2 | Not yet recruiting | NSCLC | Atezolizumab plus Tiragolumab | Atezolizumab | - | |||||||
| 79 | NCT05825625 | 2 | Not yet recruiting | NSCLC | Tiragolumab plus Atezolizumab with chemotherapy | - | - | |||||||
| 80 | NCT05746481 | 2 | Not yet recruiting | NSCLC | Tiragolumab plus Atezolizumab plus Pemetrexed plus Carboplatin | - | - | |||||||
| 81 | NCT05791097 | 3 | Not yet recruiting | NSCLC | Ociperlimab + Tislelizumab + chemotherapy |
Placebo + Pembrolizumab + chemotherapy Placebo + Tislelizumab + chemotherapy |
- | |||||||
| 82 | NCT04995523 | 1/2 | Recruiting | NSCLC | AZD2936 | - | - | |||||||
| 83 | NCT04791839 | 2 | Recruiting | NSCLC | Zimberelimab plus Domvanalimab plus Etrumadenant | - | - | |||||||
| 84 | NCT05211895 | 3 | Recruiting | NSCLC | Durvalumab plus Domvanalimab | Durvalumab plus Placebo | - | |||||||
| 85 | NCT04746924 | 3 | Recruiting | NSCLC | Tislelizumab plus Ociperlimab |
Pembrolizumab plus Placebo Tislelizumab plus Placebo |
- | |||||||
| 86 | NCT04294810 | 3 | Recruiting | NSCLC | Atezolizumab plus Tiragolumab | Atezolizumab plus Placebo | - | |||||||
| 87 | NCT04958811 | 2 | Recruiting | NSCLC | Tiragolumab plus Atezolizumab plus Bevacizumab | - | - | |||||||
| 88 | NCT04513925 | 3 | Recruiting | NSCLC | Atezolizumab plus Tiragolumab | Durvalumab | - | |||||||
| 89 | NCT05014815 | 2 | Recruiting | NSCLC | Ociperlimab plus Tislelizumab plus chemotherapy | Placebo plus Tislelizumab plus chemotherapy | - | |||||||
| 90 | NCT04619797 | 2/3 | Recruiting | NSCLC | Tiragolumab plus Atezolizumab plus chemotherapy | Placebo plus Pembrolizumab plus chemotherapy | - | |||||||
| 91 | NCT05502237 | 3 | Recruiting | NSCLC | Zimberelimab plus Domvanalimab plus chemotherapy |
Pembrolizumab plus chemotherapy Zimberelimab plus chemotherapy |
- | |||||||
| 92 | NCT04738487 | 3 | Recruiting | NSCLC | MK-7684 A (Pembrolizumab/Vibostolimab) | Pembrolizumab | - | |||||||
| 93 | NCT05298423 | 3 | Recruiting | NSCLC | MK-7684 A (Pembrolizumab/Vibostolimab) plus chemotherapy plus radiotherapy | Durvalumab plus chemotherapy plus radiotherapy | - | |||||||
| 94 | NCT04832854 | 2 | Recruiting | NSCLC |
Tiragolumab plus Atezolizumab Tiragolumab plus Atezolizumab plus chemotherapy |
chemotherapy | - | |||||||
| 95 | NCT05226598 | 3 | Recruiting | NSCLC | MK-7684 A plus chemotherapy | Pembrolizumab plus chemotherapy | - | |||||||
| 96 | NCT04866017 | 3 | Recruiting | NSCLC | Ociperlimab plus Tislelizumab plus chemoradiotherapy |
Tislelizumab plus chemoradiotherapy Durvalumab plus chemoradiotherapy |
- | |||||||
| 97 | NCT05102214 | 1/2 | Recruiting | NSCLC | HLX301 | - | - | |||||||
| 98 | NCT04736173 | 3 | Recruiting | NSCLC | Zimberelimab plus Domvanalimab |
Carboplatin plus paclitaxel or pemetrexed Zimberelimab |
- | |||||||
| 99 | NCT04612751 | 1 | Recruiting | NSCLC |
Datopotamab deruxtecan plus AZD2936 Datopotamab deruxtecan plus AZD2936 plus Carboplatin |
Datopotamab deruxtecan plus Durvalumab Datopotamab deruxtecan plus Durvalumab plus Carboplatin Datopotamab deruxtecan plus MEDI5752 Datopotamab deruxtecan plus MEDI5752 plus Carboplatin |
- | |||||||
| 100 | NCT05676931 | 2 | Recruiting | NSCLC |
Domvanalimab plus Zimberelimab Domvanalimab plus Zimberelimab plus Platinum Doublet Chemotherapy Domvanalimab plus Quemliclustat plus Zimberelimab plus Platinum Doublet Chemotherapy Domvanalimab plus Zimberelimab plus Docetaxel |
Quemliclustat plus Zimberelimab Quemliclustat plus Zimberelimab plus Platinum Doublet Chemotherapy Quemliclustat plus Zimberelimab plus Docetaxel |
- | |||||||
| 101 | NCT05633667 | 2 | Recruiting | NSCLC |
Sacituzumab Govitecan-hziy plus Zimberelimab plus Domvanalimab Etrumadenant plus Zimberelimab plus Domvanalimab |
Etrumadenant plus Zimberelimab Zimberelimab plus Platinum Based Chemotherapy Etrumadenant plus Zimberelimab plus Sacituzumab Govitecan-hziy Either Docetaxel or Sacituzumab Govitecan-hziy monotherapy |
- | |||||||
| 102 | NCT05565378 | 2 | Recruiting | NSCLC | EOS-448 plus Dostarlimab |
Pembrolizumab Monotherapy Dostarlimab Monotherapy |
- | |||||||
| 103 | NCT03739710 | 2 | Recruiting | NSCLC |
EOS-448 plus Dostarlimab EOS-448 plus Dostarlimab plus GSK6097608 |
feladilimab plus ipilimumab Docetaxel Docetaxel plus Feladilimab |
- | |||||||
| 104 | NCT04165070 | 2 | Recruiting | NSCLC |
Pembrolizumab plus Vibostolimab plus Carboplatin plus Paclitaxel Pembrolizumab plus Vibostolimab plus Carboplatin plus Pemetrexed |
Pembrolizumab plus Boserolimab plus Carboplatin plus Paclitaxel Pembrolizumab plus Boserolimab plus Carboplatin plus Pemetrexed Pembrolizumab plus MK-4830 plus Carboplatin plus Paclitaxel Pembrolizumab plus MK-4830 plus Carboplatin plus Pemetrexed Pembrolizumab plus MK-0482 plus Carboplatin plus Paclitaxel Pembrolizumab plus MK-0482 plus Carboplatin plus Pemetrexed |
- | |||||||
| 105 | NCT05577702 | 2 | Recruiting | NSCLC | Tislelizumab and Ociperlimab |
Tislelizumab Monotherapy Tislelizumab and LBL-007 |
- | |||||||
| 106 | NCT05681039 | 2 | Not yet recruiting | Oral Cavity Squamous Cell Carcinoma | Tiragolumab Plus Atezolizumab | - | - | |||||||
| 107 | NCT05715216 | 2 | Recruiting | Ovarian Cancer | Etigilimab plus Nivolumab | - | - | |||||||
| 108 | NCT05419479 | 1/2 | Recruiting | Pancreatic Cancer | domvanalimab plus Zimberelimab plus APX005M | FOLFIRI | - | |||||||
| 109 | NCT03193190 | 1/2 | Recruiting | Pancreatic Cancer | Atezolizumab plus Chemotherapy plus Tiragolumab |
Nab-Paclitaxel and Gemcitabine Atezolizumab plus Chemotherapy plus Selicrelumab Atezolizumab plus Chemotherapy plus Bevacizumab Atezolizumab plus Chemotherapy plus AB928 Atezolizumab plus Cobimetinib Atezolizumab plus PEGPH20 Atezolizumab plus BL-8040 Atezolizumab plus RO6874281 Nab-Paclitaxel and Gemcitabine or mFOLFOX6 Atezolizumab plus Chemotherapy plus Tocilizumab |
- | |||||||
| 110 | NCT05009069 | 2 | Recruiting | Rectal Cancer | Tiragolumab plus Atezolizumab plus radiotherapy | Atezolizumab | - | |||||||
| 111 | NCT04626479 | 1/2 | Recruiting | Renal Cell Carcinoma | MK-7684 A plus Belzutifan |
Coformulation Pembrolizumab/Quavonlimab plus Lenvatinib Coformulation Favezelimab/Pembrolizumabplus Lenvatinib Pembrolizumab plus Belzutifan plus Lenvatinib Pembrolizumab plus Lenvatinib |
- | |||||||
| 112 | NCT05805501 | 2 | Recruiting | Renal Cell Carcinoma | RO7247669 plus Tiragolumab plus Axitinib |
RO7247669 plus Axitinib Pembrolizumab plus Axitinib |
- | |||||||
| 113 | NCT04952597 | 2 | Active, not recruiting | SCLC | Ociperlimab plus Tislelizumab plus chemoradiotherapy |
Tislelizumab plus Concurrent Chemoradiotherapy Concurrent Chemoradiotherapy |
- | |||||||
| 114 | NCT04256421 | 3 | Active, not recruiting | SCLC | Tiragolumab plus Atezolizumab plus chemotherapy | Placebo plus Atezolizumab plus chemotherapy |
mPFSdual+C: 5.4 m vs. mPFSP+C: 5.6 m (HR = 1.11) mOSdual+C: 13.6 m vs. mOSP+C: 13.6 m (HR = 1.04) DoRdual+C: 4.2 m vs. DoRP+C: 5.1 m |
|||||||
| 115 | NCT04308785 | 2 | Active, not recruiting | SCLC | Atezolizumab plus Tiragolumab | Atezolizumab plus Placebo | - | |||||||
| 116 | NCT04665856 | 3 | Active, not recruiting | SCLC | Tiragolumab plus Atezolizumab plus chemotherapy | Placebo plus Atezolizumab plus chemotherapy | - | |||||||
| 117 | NCT05224141 | 3 | Recruiting | SCLC | MK-7684 A plus chemotherapy | Atezolizumab plus chemotherapy | - | |||||||
| 118 | NCT04665843 | 2 | Active, not recruiting | Squamous Cell Carcinoma of Head and Neck | Atezolizumab plus Tiragolumab | Atezolizumab plus Placebo | - | |||||||
| 119 | NCT03708224 | 2 | Recruiting | Squamous Cell Carcinoma of Head and Neck | Atezolizumab plus Tiragolumab |
Atezolizumab plus Tocilizumab Atezolizumab Monotherapy Atezolizumab (Adjuvant) |
- | |||||||
| 120 | NCT05459129 | 1/2 | Recruiting | Squamous Cell Carcinoma of Head and Neck |
Atezolizumab plus Tiragolumab Atezolizumab plus Tiragolumab plus Carboplatin plus Paclitaxel |
- | - | |||||||
| 121 | NCT05661188 | 2 | Not yet recruiting | Squamous Cell Carcinoma of the Anal Canal | Atezolizumab plus Tiraglolumab plus chemotherapy | - | - | |||||||
| 122 | NCT04584112 | 1 | Active, not recruiting | Triple Negative Breast Cancer | Tiragolumab plus Atezolizumab plus chemotherapy | - | - | |||||||
| 123 | NCT05809895 | 2 | Not yet recruiting | Triple Negative Breast Cancer | ociperlimab + tislelizumab + chemotherapy |
Placebo + pembrolizumab + chemotherapy Placebo + tislelizumab + chemotherapy |
- | |||||||
| 124 | NCT05267054 | 1/2 | Recruiting | B-cell Lymphoma |
Ociperlimab plus Tislelizumab Ociperlimab plus Rituximab |
- | - | |||||||
| 125 | NCT05315713 | 1/2 | Active, not recruiting | Hematological Malignancies |
Mosunetuzumab SC plus Tiragolumab Mosunetuzumab SC plus Tiragolumab plus Atezolizumab |
- | - | |||||||
| 126 | NCT05005442 | 2 | Recruiting | Hematological Malignancies | Pembrolizumab plus vibostolimab | - | - | |||||||
| 127 | NCT04150965 | 1/2 | Recruiting | Multiple Myeloma |
BMS-986,207 BMS-986,207 plus Pomalidimide plus Dexamethasone |
Elotuzumab plus pomalidomide plus dexamethasone Anti-LAG-3 Anti-LAG-3 plus Pomalidimide plus Dexamethasone |
- | |||||||
| 128 | NCT05289492 | 1/2 | Recruiting | Multiple Myeloma |
EOS-448 EOS-448 plus Iberdomide EOS-448 plus Iberdomide plus Dexamethasone |
- | - | |||||||
| 129 | NCT05061628 | 1 | Recruiting |
Mixed Tumors: Advanced Solid Tumor Lymphoma |
JS006 plus Toripalimab JS006 |
- | - | |||||||
| 130 | NCT05390528 | 1/2 | Recruiting |
Mixed Tumors: Advanced Solid Tumor Lymphoma |
HLX301 | - | - | |||||||
| 131 | NCT04254107 | 1 | Recruiting |
Mixed Tumors: Advanced Solid Tumor Lymphoma |
SEA-TGT SEA-TGT plus sasanlimab SEA-TGT plus brentuximab vedotin |
- | - | |||||||
| 132 | NCT04772989 | 1 | Recruiting |
Mixed Tumors: Advanced Solid Tumor Lymphoma |
AB308 plus Zimberelimab | - | - | |||||||
Abbr. NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer; ESCC = esophageal squamous cell carcinoma; dual = dual TIGIT and PD-(L)1 inhibitors; P = PD-(L)1 inhibitor; dual + C = dual TIGIT and PD-(L)1 inhibitors combined with chemotherapy; P + C = PD-(L)1 inhibitor combined with chemotherapy; dual + O = dual TIGIT and PD-(L)1 inhibitors combined with other inhibitors